The announcement comes as the Danish drugmaker struggles to grab significant market share in the Indian market before it ...

Novo Nordisk India and Emcure Pharma announced a strategic partnership on Monday to launch Poviztra (semaglutide injection 2.4 mg) in India. The collaboration aims to enhance the distribution and ...

Novo Nordisk India partners with Emcure Pharma to distribute and market Poviztra (semaglutide) nationwide, expanding access ...

Emcure Pharma becomes the first Indian company to hold exclusive rights to distribute and commercialise Poviztra, a ...

Novo Nordisk India and Emcure Pharma have partnered to launch Poviztra (semaglutide 2.4 mg), a second brand of Wegovy®, in ...

This collaboration combines Novo Nordisk’s innovation in GLP-1 therapies with Emcure’s marketing and distribution strengths ...

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide ...

The Indian subsidiary of Danish pharma major Novo Nordisk has partnered with Pune-based Emcure Pharma to expand the reach of ...

The deal will help expand the availability and marketing of this weight-loss medicine, especially in areas where Novo Nordisk ...

Novo Nordisk and Emcure Pharma team up to bring Poviztra, a new weight loss injection, to India. Learn more about this latest ...

() -​Novo ‌Nordisk has partnered ‌with India's Emcure Pharmaceuticals ⁠to ‌exclusively distribute and ‍market weight-loss ...

Novo Nordisk has partnered with India's Emcure Pharmaceuticals to exclusively distribute and market its weight-loss drug ...